Ecopipam: Phase IIa started

Psyadon began an open-label, U.S. Phase IIa to evaluate 50 and 100 mg once-daily ecopipam for 8 weeks in about 16 adult patients. Psyadon has exclusive, worldwide rights to ecopipam from Schering-Plo...